Table 1 Patients’ clinical baseline characteristics (n = 17)
Whole cohort (n = 17) | Responders (n = 10) | Non-responders (n = 7) | ||
|---|---|---|---|---|
Demographics | ||||
Age in years, mean (±SD; range) | 53.9 (± 16.7; 20–76) | 57.1 (± 9.7; 43–70) | 49.3 (± 23.7; 20–76) | |
Gender, n (%) | Female | 10 (58.5%) | 6 (60.0%) | 4 (57.1%) |
Male | 7 (41.2%) | 4 (40.0%) | 3 (42.9%) | |
Body mass index, mean (±SD; range) | 25.9 (± 5.2; 17–39) | 28.4 (± 4.8; 23–39)* | 22.4 (± 4.5; 17–30)* | |
Smokers, n (%) | Yes | 7 (43.8%) | 6 (60.0%) | 1 (14.3%) |
Psychometric characteristics | ||||
Age at diagnosis in years, mean (±SD; range) | 33.6 (± 17.1; 14–74) | 31.3 (± 14.0; 14–53) | 36.8 (± 21.5; 18–74) | |
Current episode in weeks, mean (±SD; range) | 36.3 (± 33.6; 3–124) | 35.0 (± 38.7; 3–124) | 39.0 (± 25.2; 16–68) | |
BDI, mean (±SD; range) | 36.4 (± 10.9; 16–56) | 35.3 (± 12.1; 16–56) | 38.3 (± 9.2; 24–52) | |
MADRS, mean (±SD; range) | 32.8 (± 10.3; 12–45) | 33.8 (± 12.5; 12–45) | 31.5 (± 7.4; 24–45) | |
MMSE, mean (±SD; range) | 28.5 (± 2.6; 21–30) | 28.0 (± 3.3; 21–30) | 29.2 (± 1.3; 27–30) | |
Psychotic symptoms, n (%) | Yes | 5 (29.4%) | 3 (30.0%) | 2 (28.6%) |
Suicidality, n (%) | Yes | 3 (17.6%) | 0 (0.0%) | 3 (42.9%) |
Medication | ||||
Antidepressant drugs, n (%) | Yes | 17 (100.0%) | 10 (100.0%) | 7 (100.0%) |
Benzodiazepines, n (%) | Yes | 11 (64.7%) | 7 (70.0%) | 4 (57.1%) |
Antipsychotic drugs, n (%) | Yes | 11 (64.7%) | 8 (80.0%) | 3 (42.9%) |
Lithium, n (%) | Yes | 3 (17.6%) | 1 (10.0%) | 2 (28.6%) |
Clinical parameters | ||||
Leukocytes in × 103/μl, mean (±SD; range) | 7.6 (± 2.8; 3.5–12.4) | 8.6 (± 2.4; 6.4–12.4) | 6.2 (± 2.8; 3.5–12.1) | |